Making headway: Bioven’s contract research partners include the Beatson Cancer Institute in Glasgow, Scotland, Pangea Biotech in Catalan, Spain and International Medical University (IMU) in Malaysia (pictured, research scientist Sylvia Gan at IMU). Photos: AZMAN GHANI/The Star
Tan Sri Datuk Dr Abu Bakar Suleiman (L) and Johan Indot are chairman and executive director of Bioven– the company set up to enter the generic drug import business – the Malaysian company which has emerged as a dark horse in a drug development space dominated by big pharma. Photo: Azman Ghani/The Star
Bioven's significance to Malaysia's biotech sector: There is still a scarcity of investment advisers with sufficient expertise to make recommendations in this niche industry
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
